Congress must act before Big Pharma greed breaks Medicare
Congress
Pharma corporation Biogen is pricing its new Alzheimer’s drug Aduhelm at $56,000 per year. Yet the Food and Drug Administration’s independent advisory committee opposed approving the drug, citing insufficient evidence.
Biogen greedily set a price that could DOUBLE Medicare’s prescription drug spending, and it’s not even clear the drug works.
It’s unacceptable for seniors and taxpayers to pay such an outrageous price for any drug.
Sponsored by
.png)
To:
Congress
From:
[Your Name]
$56,000 a year. One drug. It may not even work. It could DOUBLE Medicare’s prescription drug spending. This is why we need Medicare negotiation NOW.